

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number
WO 02/100853 A1

(51) International Patent Classification⁷: **C07D 401/06**,
409/06, 403/06, 405/12, 231/18, A61K 31/415, 31/506,
31/4427, A61P 31/18

(21) International Application Number: PCT/EP02/05898

(22) International Filing Date: 29 May 2002 (29.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0113524.3 4 June 2001 (04.06.2001) GB

(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH];
124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: **DYMOCK, Brian, William**; 15 Vesta Avenue,
St. Albans, Hertfordshire AL1 2PJ (GB). **GILL, Adrian,
Liam**; 34 Dane Lane, Wilshamstead, Bedfordshire MK45
3HT (GB). **JONES, Philip, Stephen**; 58 Digswell rise,
Welwyn Garden City, Hertfordshire AL8 7PW (GB).
PARKES, Kevin, Edward, Burdon; 60 Hallmead,
Letchworth, Hertfordshire SG6 4BJ (GB). **PARRATT,
Martin, John**; 22 Chapel Lane, Letty Green, Hertford,
Hertfordshire SG14 2PA (GB).

(74) Agent: **RAUBER, Beat**; 124 Grenzacherstrasse, CH-4070
Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS

(57) Abstract: The invention is concerned with novel pyrazole derivatives, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine. In particular, the compounds of formula I are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. Consequently the compounds of this invention may be advantageously used as therapeutic agents for HIV mediated process. The invention describes novel compounds of formula I wherein R¹, R², R³ and A are as defined in the description; ethers of compounds of formula I as well as pharmaceutically acceptable salts of the foregoing.



WO 02/100853 A1

PYRAZOLE DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Pyrazole Derivatives II

The invention is concerned with novel pyrazole derivatives, processes for their manufacture, pharmaceutical compositions and the use of such compounds in medicine, especially in the treatment of viral diseases. In particular, the compounds are inhibitors of
5 the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication. Consequently the compounds of this invention may be advantageously used as therapeutic agents for the treatment of diseases mediated by the human immunodeficiency virus (HIV).

The disease Acquired Immunodeficiency Syndrome (AIDS) is the end result of
10 infection by the distinct retroviruses, human immunodeficiency virus type-1 (HIV-1) or type-2 (HIV-2). Several critical points in the virus life cycle have been identified as possible targets for therapeutic intervention. Inhibition of one of these, the transcription of viral RNA to viral DNA (controlled by reverse transcriptase, RT), has provided a number of the current therapies used in treating AIDS. Inhibition of reverse transcriptase provided the
15 first form of treatment for HIV infection with 3'-azido-3'-deoxythymidine (AZT). Since then several inhibitors have been launched, broadly forming two classes: nucleoside analogues and non-nucleosides. As an example of the latter it has been found that certain benzoxazinones, e.g. efavirenz, are useful in the inhibition of HIV RT. However, development of strains of the virus resistant to current RT inhibitors is a constant
20 problem. Therefore, development of compounds effective against resistant strains is an important goal.

Pyrazole derivatives have been described in the literature with different uses (e.g. agrochemistry or treatment of stress-relating illness).


EP 0 627 423 describes pyrazole derivatives and their use as agrohorticultural
25 bactericides.

US 6,005,109 describes pyrazole derivatives and their use in the treatment of stress-relating illness.

US 5,786,302 describes pyrazole derivatives and their use as herbicides.

The object of the present invention is to provide pyrazole compounds which are potent inhibitors of the human immunodeficiency virus reverse transcriptase enzyme (HIV RT) which is involved in viral replication, and which accordingly show a potential to be efficacious as antiviral drugs.

This object can be achieved with compounds of formula I



wherein

R¹ is alkyl or substituted alkyl;

R² is aryl or substituted aryl;

R³ is hydroxy, amino, azido, hydroxy-C₁₋₄-alkyl, C₁₋₄-alkyl-sulfonyl-amino or a group of the formula -X-C(=O)-Z,

wherein X represents NR^{'''}, O or a single bond; wherein R^{'''} is hydrogen or C₁₋₄-alkyl, and

wherein Z is C₁₋₄-alkyl, C₁₋₄-alkoxy or NR^{''}R^{'''}; wherein R^{''}, R^{'''} are independently of each other hydrogen or C₁₋₄-alkyl;

A signifies alkyl, substituted alkyl, aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methyl, substituted heterocyclyl-methyl, heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl;

with ethers of compounds of formula I as well as with pharmaceutically acceptable salts of the foregoing.

The term "alkyl" as used herein, and if not specified by the number of carbon atoms, denotes an optionally substituted straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl

including their different isomers. The term "C₁₋₁₂-alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms as defined above. The term "C₁₋₇-alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms. The term "C₁₋₄-alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 4 carbon atoms.

Suitable substituents for the alkyl group are 1-6 fluorine substituents or 1-3 hydroxy substituents, preferably 1-3 fluorine substituents or 1-2 hydroxy substituents and most preferably 3 fluorine substituents or 1 hydroxy substituent. In case more than one substituent is attached to the alkyl group, these substituents can be identical or different from each other.

Alkyl in R¹ is preferably a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms as defined above. More preferably the alkyl group in R¹ is a straight or branched chain hydrocarbon residue containing 1 to 7 carbon atoms. In another preferred embodiment alkyl in R¹ is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert.-butyl. Most preferred alkyl in R¹ is isopropyl.

Substituted alkyl for R¹ is preferably a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms as defined above substituted with 1-6 fluorine substituents, most preferably the trifluoromethyl group.

Alkyl for the substituent A is preferably a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms as defined above. More preferred alkyl groups in R¹ are straight or branched chain hydrocarbon residues containing 1 to 7 carbon atoms. Most preferred alkyl in R¹ is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert.-butyl.

Substituted alkyl for the substituent A is preferably a straight or branched chain hydrocarbon residue containing 1 to 12 carbon atoms as defined above substituted with 1-3 hydroxy groups, most preferably the hydroxy-methyl group.

The term "hydroxy-C₁₋₄-alkyl" as used herein denotes a C₁₋₄-alkyl, preferably a C₁₋₂-alkyl as defined above which is substituted with a hydroxy group. Examples are hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl.

The term "C₁₋₄-alkyl-sulfonyl-amino" as used herein for the substituent R³ denotes for example a methanesulfonamide, ethanesulfonamide, propanesulfonamide or butanesulfonamide. The NH-function of C₁₋₄-alkyl-sulfonyl-amino can as well be alkylated with C₁₋₄-alkyl as defined above, preferably methyl or ethyl.

The term "alkoxy" as used herein, denotes a straight or branched chain alkyl-oxy group wherein the "alkyl" portion is as defined above such as methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, tert.-butyloxy. More preferred alkoxy groups within the invention are methoxy or ethoxy.

5 Formula " $-X-C(=O)-Z$ " as used herein denotes a chemical group wherein X represents NR'''' , O or a single bond (wherein R'''' is hydrogen or C_{1-4} -alkyl); and wherein Z is C_{1-4} -alkyl, C_{1-4} -alkoxy or $NR''R'''$ (wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl). Preferably, the formula " $-X-C(=O)-Z$ " as used herein denotes a chemical group wherein X represents NR'''' or O (wherein R'''' is hydrogen or C_{1-4} -alkyl);
 10 and wherein Z is C_{1-4} -alkyl, C_{1-4} -alkoxy or $NR''R'''$ (wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl). More preferred, the formula " $-X-C(=O)-Z$ " as used herein denotes a chemical group wherein X represents NR'''' or O (wherein R'''' is hydrogen or C_{1-4} -alkyl); and wherein Z is $NR''R'''$ (wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl). Most preferred, the formula " $-X-C(=O)-Z$ " as used
 15 herein denotes a chemical group wherein X represents O (wherein R'''' is hydrogen or C_{1-4} -alkyl); and wherein Z is $NR''R'''$ (wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl). Examples of the chemical group of formula " $-X-C(=O)-Z$ " are amino-carbonyl-oxy, methyl-amino-carbonyl-oxy, di-methyl-amino-carbonyl-oxy, amino-carbonyl-amino, methyl-amino-carbonyl-amino, di-methyl-amino-carbonyl-
 20 amino, amino-carbonyl-(methyl)-amino, methyl-amino-carbonyl-(methyl)-amino, di-methyl-amino-carbonyl-(methyl)-amino, methoxy-carbonyl-amino, methoxy-carbonyl-(methyl)-amino, ethoxy-carbonyl-amino or ethoxy-carbonyl-(methyl)-amino.

The term "aryl" as used herein denotes an optionally substituted phenyl and naphthyl, both optionally benz-fused to an optionally substituted saturated, partially
 25 unsaturated or aromatic monocyclic, bicyclic or tricyclic heterocycle or carbocycle e.g. to cyclohexyl or cyclopentyl. Preferably the term "aryl" as used herein denotes an optionally substituted phenyl group.

Suitable substituents for aryl (preferably phenyl) can be selected from 1-5 substituents selected from C_{1-4} -alkyl, substituted C_{1-4} -alkyl, C_{1-4} -alkoxy, C_{1-4} -alkylthio, fluorine, chlorine, bromine and cyano; wherein substituted C_{1-4} -alkyl means C_{1-4} -alkyl
 30 substituted with 1-3 substituents selected from hydroxy, C_{1-4} -alkoxy, $CONH_2$, NRR' and wherein R and R' are independently of each other hydrogen, C_{1-4} -alkyl or $-C(=O)CH_3$.

In case more than one substituent is attached to the aryl group, these substituents can be identical or different from each other.

Aryl in R² is an unsubstituted or substituted phenyl or naphthyl (preferably phenyl) with suitable substituents selected from 1 to 5 substituents, preferably 1-4 substituents, more preferably 1-3 substituents selected from C₁₋₄-alkyl (preferably C₁₋₂-alkyl), substituted C₁₋₄-alkyl (preferably substituted C₁₋₂-alkyl), C₁₋₄-alkoxy (preferably C₁₋₂-alkoxy), C₁₋₄-alkylthio (preferably C₁₋₂-alkylthio), fluorine, chlorine, bromine and cyano; wherein substituted C₁₋₄-alkyl (preferably substituted C₁₋₂-alkyl) means C₁₋₄-alkyl (preferably C₁₋₂-alkyl) substituted with 1-3 substituents (preferably 1-2 substituents, more preferred 1 substituent) selected from hydroxy, C₁₋₄-alkoxy (preferably C₁₋₂-alkoxy), CONH₂ and NRR'; and wherein R and R' are independently of each other hydrogen, C₁₋₄-alkyl (preferably C₁₋₂-alkyl) or -C(=O)CH₃. In case more than one substituent is attached to the aryl group, these substituents can be identical or different from each other.

Preferred substituents for the phenyl group are 1-5 substituents (more preferred 1-3 substituents) selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, fluorine, chlorine, bromine and cyano (more preferred fluorine, chlorine, bromine and cyano). Most preferred substituents for the phenyl group are 1-5 substituents (more preferred 1-3 substituents) selected from chlorine and cyano. Examples of substituted aryl groups are 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-ethyl-phenyl, 3-ethyl-phenyl, 4-ethyl-phenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 3,6-dimethylphenyl, 2,4,6-trimethylphenyl, 3,4,5-trimethylphenyl, 2,3,4-trimethylphenyl, 2,4,5-trimethylphenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2,5-dimethoxy-phenyl, 2,6-dimethoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 3,6-dimethoxy-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3,6-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3,6-dichlorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trichlorophenyl, 2,3,4-trichlorophenyl, 2,4,5-trichlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2,3-dibromophenyl, 2,4-dibromophenyl, 2,5-dibromophenyl, 2,6-dibromophenyl, 3,4-dibromophenyl, 3,5-dibromophenyl, 3,6-dibromophenyl, 2-cyano-phenyl, 3-cyano-phenyl, 4-cyano-phenyl, 2,3-di-cyano-phenyl, 2,4-di-cyano-phenyl, 2,5-di-cyano-phenyl, 2,6-di-cyano-phenyl, 3,4-di-cyano-phenyl, 3,5-di-cyano-phenyl, 3,6-di-cyano-phenyl, 2-(hydroxymethyl)phenyl, 3-(hydroxymethyl)phenyl, 4-(hydroxymethyl)phenyl, 2-chloro-4-fluorophenyl, 2-chloro-6-methyl-phenyl, 3-chloro-5-bromo-phenyl, 3-chloro-5-propyl-phenyl, 3-chloro-5-methyl-phenyl, 3-chloro-5-ethyl-phenyl, 3-chloro-5-(hydroxymethyl)-phenyl, 3-chloro-5-cyano-phenyl, 3-chloro-5-(1,2-propanediol)-phenyl or 2-naphthyl. Preferred example for aryl in R² is 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 3,4-

dichlorophenyl, 3,5-dichlorophenyl, 3,6-dichlorophenyl, 2,4,6-trichlorophenyl, 3,4,5-trichlorophenyl, 2,3,4-trichlorophenyl, 2,4,5-trichlorophenyl. More preferred example for aryl in R² is 3,5-dichlorophenyl.

Aryl in aryl-methyl for the substituent A is as defined above, preferably phenyl.

5 Substituted aryl in substituted aryl-methyl for the substituent A is as defined above, with suitable substituents selected from 1 to 5 substituents, preferably 1-4 substituents, more preferably 1-3 substituents selected from C₁₋₄-alkoxy (preferably C₁₋₂-alkyl), fluorine, chlorine and bromine. In case more than one substituent is attached to the aryl group, these substituents can be identical or different from each other. Examples for substituted
10 aryl in substituted aryl-methyl are preferably 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2,5-dimethoxy-phenyl, 2,6-dimethoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 3,6-dimethoxy-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-
15 difluorophenyl or 3,6-difluorophenyl.

Aryl in aryl-methoxy-methyl for the substituent A is as defined above, preferably phenyl.

Substituted aryl in substituted aryl-methoxy-methyl, for the substituent A is as defined above, with suitable substituents selected from 1 to 5 substituents, preferably 1-4
20 substituents, more preferably 1-3 substituents selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-alkylamino, hydroxy, cyano, amino, mercapto groups, fluorine, chlorine and bromine. In case more than one substituent is attached to the aryl group, these substituents can be identical or different from each other. Examples for substituted
25 aryl in substituted substituted aryl-methoxy-methyl are 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2,3-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 2,5-dimethoxy-phenyl, 2,6-dimethoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 3,6-dimethoxy-phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl or 3,6-difluorophenyl.

30 The term "heterocyclyl" as used herein denotes an aromatic or non-aromatic monocyclic or bicyclic heterocyclic system which contains 1, 2, 3 or 4 hetero atoms, preferably 1, 2 or 3 hetero atoms, with the hetero atoms being selected from nitrogen, oxygen and sulfur. Examples of heterocyclyl are 2-furyl, 3-furyl, 1-pyrrolyl, 2-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 1-indolyl, 2-indolyl or 3-indolyl, pyridazin-3-yl, pyridazin-4-
35 yl, 2-thienyl, 3-thienyl, [1,3,4]thiadiazol-2-yl, [1,3,4]thiadiazol-5-yl, or tetrahydro-pyran-

4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, 1H-imidazol-5-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl, pyrrolidin-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl or pyrimidin-6-yl.

Suitable substituents for heterocyclyl can be selected from 1,2,3 or 4 (where
 5 chemically possible), preferably 1 or 2, selected from C₁₋₄-alkyl (preferably C₁₋₂-alkyl), C₁₋₄-alkoxy (preferably C₁₋₂-alkoxy), C₁₋₄-alkylthio (preferably C₁₋₂-alkylthio), C₁₋₄-alkylamino (preferably C₁₋₂-alkylamino), hydroxy, cyano, amino, mercapto groups, fluorine, chlorine and bromine.

In case more than one substituent is attached to the aryl group, these substituents
 10 can be identical or different from each other.

Heterocyclyl in heterocyclyl-methyl or heterocyclyl-methoxy-methyl for the
 substituent A is as defined above, preferably 1-furyl, 2-furyl, 1-pyrrolyl, 2-pyrrolyl, 1-
 thiophenyl, 2-thiophenyl, 2-pyridyl, 3-pyridyl or 4-pyridyl, more preferred 2-pyridyl, 3-
 pyridyl, 4-pyridyl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl or pyrimidin-6-yl.
 15 Preferred heterocyclyl in heterocyclyl-methyl or heterocyclyl-methoxy-methyl is pyridyl,
 most preferred 4-pyridyl.

Substituted heterocyclyl in substituted heterocyclyl-methyl or substituted
 heterocyclyl-methoxy-methyl for the substituent A are as defined above. Suitable
 substituents for heterocyclyl are selected from 1, 2, 3 or 4 substituents, preferably 1, 2 or 3
 20 substituents, more preferably 1 or 2 substituents, and most preferably 1 substituent,
 wherein these substituents are selected from C₁₋₄-alkyl (preferably C₁₋₂-alkyl), C₁₋₄-alkoxy
 (preferably C₁₋₂-alkoxy), C₁₋₄-alkylthio (preferably C₁₋₂-alkylthio), C₁₋₄-alkylamino
 (preferably C₁₋₂-alkylamino), hydroxy, cyano, amino, mercapto groups, fluorine, chlorine
 and bromine. Preferred substituents for heterocyclyl are selected from 1, 2, 3 or 4
 25 substituents, preferably 1, 2 or 3 substituents, more preferably 1 or 2 substituents, and
 most preferably 1 substituent, wherein these substituents are selected from 1-4 substituents
 selected from C₁₋₄-alkyl, fluorine, chlorine and bromine. More preferred substituents for
 heterocyclyl are selected from 1, 2, 3 or 4 substituents, preferably 1, 2 or 3 substituents,
 more preferably 1 or 2 substituents, and most preferably 1 substituent, wherein these
 30 substituents are selected from C₁₋₄-alkyl and bromine. Examples for substituted
 heterocyclyl are 2-methyl-pyridyl, 3-methyl-pyridyl, 4-methyl-pyridyl, 2,3-
 dimethylpyridyl, 2,4-dimethylpyridyl, 2,5-dimethylpyridyl, 2,6-dimethylpyridyl, 3,4-
 dimethylpyridyl, 3,5-dimethylpyridyl, 3,6-dimethylpyridyl, 2-methoxy-pyridyl, 3-
 methoxy-pyridyl, 4-methoxy-pyridyl, 2,3-dimethoxy-pyridyl, 2,4-dimethoxy-pyridyl, 2,5-
 35 dimethoxy-pyridyl, 2,6-dimethoxy-pyridyl, 3,4-dimethoxy-pyridyl, 3,5-dimethoxy-
 pyridyl, 3,6-dimethoxy-pyridyl, 2-fluoro-pyridyl, 3-fluoro-pyridyl, 4-fluoro-pyridyl, 2,3-

5 difluoro-pyridyl, 2,4-difluoro-pyridyl, 2,5-difluoro-pyridyl, 2,6-difluoro-pyridyl, 3,4-difluoro-pyridyl, 3,5-difluoro-pyridyl, 3,6-difluoro-pyridyl, 2-chloro-pyridyl, 3-chloro-pyridyl, 4-chloro-pyridyl, 2,3-dichloro-pyridyl, 2,4-dichloro-pyridyl, 2,5-dichloro-pyridyl, 2,6-dichloro-pyridyl, 3,4-dichloro-pyridyl, 3,5-dichloro-pyridyl, 3,6-dichloro-pyridyl, 2-bromo-pyridyl, 3-bromo-pyridyl, 4-bromo-pyridyl, 2,3-dibromo-pyridyl, 2,4-dibromo-pyridyl, 2,5-dibromo-pyridyl, 2,6-dibromo-pyridyl, 3,4-dibromo-pyridyl, 3,5-dibromo-pyridyl, 3,6-dibromo-pyridyl, 5-bromo-2-methyl-pyrimidin-4-yl, 2-bromo-5-methyl-pyrimidin-4-yl, 5-bromo-6-methyl-pyrimidin-4-yl, 6-bromo-2-methyl-pyrimidin-4-yl, 6-bromo-5-methyl-pyrimidin-4-yl, 5-bromo-pyrimidin-4-yl, 5-methyl-pyrimidin-4-yl, 2-bromo-pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 6-bromo-pyrimidin-4-yl or 6-methyl-pyrimidin-4-yl. For all the cited examples for "substituted heterocycl" these substituents can be at any chemically possible position. For example methylpyridyl means that the methyl substituent may be attached in the 3, 4, 5 or 6 position of a 2-pyridyl or in the 2, 4, 5 or 6 position of a 3-pyridyl or in the 2, 3, 5 or 6 position of a 4-pyridyl.

15 Any functional (i.e. reactive) group present in a side-chain may be protected, with the protecting group being a group which is known per se, for example, as described in "Protective Groups in Organic Synthesis", 2nd Ed., T.W. Greene and P.G.M. Wuts, John Wiley & Sons, New York, NY, 1991. For example, an amino group can be protected by tert.-butoxycarbonyl (BOC) or benzyloxycarbonyl (Z).

20 Compounds of formula I which are acidic can form pharmaceutically acceptable salts with bases such as alkali metal hydroxides, e.g. sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides, e.g. calcium hydroxide, barium hydroxide and magnesium hydroxide, and the like; with organic bases e.g. N-ethyl piperidine, dibenzylamine, and the like. Those compounds of formula (I) which are basic can form
25 pharmaceutically acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric acid and hydrobromic acid, sulphuric acid, nitric acid and phosphoric acid, and the like, and with organic acids, e.g. with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulphonic acid and p-toluene sulphonic acid, and the like. The formation and isolation of such salts can be
30 carried out according to methods known in the art.

Preferred embodiments of the invention are novel compounds of formula I wherein R^1 is C_{1-12} -alkyl or C_{1-12} -alkyl substituted with 1-6 fluorines, preferably wherein

R¹ is C₁₋₁₂-alkyl,

more preferred wherein

R¹ is C₁₋₇-alkyl,

most preferred wherein

5 R¹ is C₁₋₄-alkyl;

R² is aryl or substituted aryl,

10 wherein substituted aryl means aryl substituted with 1-5 substituents selected from C₁₋₄-alkyl, substituted C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, fluorine, chlorine, bromine and cyano; and wherein substituted C₁₋₄-alkyl means C₁₋₄-alkyl substituted with 1-3 substituents selected from hydroxy, C₁₋₄-alkoxy, CONH₂ and NRR',

wherein R and R' are independently of each other hydrogen, C₁₋₄-alkyl or -C(=O)CH₃,

preferably wherein

15 R² is phenyl or substituted phenyl,

wherein substituted phenyl means phenyl substituted with 1-5 substituents selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, fluorine, chlorine, bromine and cyano,

more preferred wherein

20 R² is substituted phenyl,

wherein substituted phenyl means phenyl substituted with 1-5 substituents selected from fluorine, chlorine, bromine and cyano,

most preferred wherein

R² is substituted phenyl,

25 wherein substituted phenyl means phenyl substituted with 1-3 substituents selected from fluorine, chlorine, bromine and cyano;

R^3 is hydroxy, amino, azido, hydroxy- C_{1-4} -alkyl, C_{1-4} -alkyl-sulfonyl-amino or a group of the formula $-X-C(=O)-Z$,

wherein X represents NR'''' , O or a single bond; wherein R'''' is hydrogen or C_{1-4} -alkyl, and

5 wherein Z is C_{1-4} -alkyl, C_{1-4} -alkoxy or $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl,

preferably wherein

R^3 is hydroxy, amino, azido, C_{1-4} -alkyl-sulfonyl-amino or a group of the formula $-X-C(=O)-Z$,

10 wherein X represents NR'''' or O; wherein R'''' is hydrogen or C_{1-4} -alkyl, and

wherein Z is C_{1-4} -alkyl, C_{1-4} -alkoxy or $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl,

more preferred wherein

15 R^3 is hydroxy or a group of the formula $-X-C(=O)-Z$,

wherein X represents NR'''' or O; wherein R'''' is hydrogen or C_{1-4} -alkyl, and

wherein Z is $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl,

20 most preferred wherein

R^3 is a group of the formula $-X-C(=O)-Z$,

wherein X represents NR'''' or O; wherein R'''' is hydrogen or C_{1-4} -alkyl, and

25 wherein Z is $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl;

A signifies C_{1-12} -alkyl, hydroxy-methyl, aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methyl, substituted

heterocyclyl-methyl, heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl,

5 wherein substituted aryl-methyl means aryl substituted with 1-5
 substituents selected from C₁₋₄-alkoxy, fluorine, chlorine and bromine,
 and

 wherein substituted aryl-methoxy-methyl means aryl substituted with 1-
 5 substituents, substituted heterocyclyl-methyl or substituted
 heterocyclyl-methoxy-methyl means heterocyclyl substituted with 1-4
10 substituents, the substituents selected from C₁₋₄-alkyl, C₁₋₄-alkoxy,
 C₁₋₄-alkylthio, C₁₋₄-alkylamino, hydroxy, cyano, amino, mercapto,
 fluorine, chlorine and bromine,

preferably wherein

A signifies heterocyclyl-methyl, substituted heterocyclyl-methyl or heterocyclyl-methoxy-methyl,

15 wherein substituted heterocyclyl-methyl means heterocyclyl substituted
 with 1-4 substituents selected from C₁₋₄-alkyl, fluorine, chlorine and
 bromine,

more preferred wherein

20 A signifies heterocyclyl-methyl, substituted heterocyclyl-methyl or heterocyclyl-methoxy-methyl,

 wherein substituted heterocyclyl-methyl means heterocyclyl substituted
 with 1-2 substituents selected from C₁₋₄-alkyl and bromine,

most preferred wherein

A signifies heterocyclyl-methyl;

25 with ethers of compounds of formula I as well as with pharmaceutically acceptable salts of
 the foregoing.

A further preferred embodiment of the invention are novel compounds of formula I
wherein

R¹ is iso-propyl;

R² is substituted phenyl,

wherein substituted phenyl means phenyl substituted with 1-3 substituents selected from chlorine and cyano;

5 R³ is a group of the formula -X-C(=O)-Z,

wherein X represents O, and








wherein Z is NR''R'''; wherein R'', R''' are independently of each other hydrogen or C₁₋₄-alkyl;










A signifies pyridyl-methyl;

10 with ethers of compounds of formula I as well as with pharmaceutically acceptable salts of the foregoing.





Specific embodiments of the present invention are compounds of formula I listed in table 1, as well as their ethers and pharmaceutically acceptable salts thereof:

Table 1

Structure	Systematic Name
	5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol
	Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester
	Methylcarbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester
	5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine
	1-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]urea
	N-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]methanesulfonamide
	Methyl [[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]carbamate

	5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazole-3-methanol
	Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazol-3-yl]methyl ester
	Carbamic acid [5-(3,5-dicyanophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester
	5-(3,5-Dichlorophenylthio)-1-ethyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol
	5-(3,5-Dichlorophenylthio)-1-isopropyl-4-(2-thenyl)-1H-pyrazole-3-methanol
	5-(3,5-Difluorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol
	Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-(2-thenyl)-1H-pyrazol-3-yl]methyl ester
	Carbamic acid [5-(3,5-difluorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester
	5-(3-Bromo-5-chlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol

	4-[(5-Bromo-2-methyl-4-pyrimidinyl)methyl]-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazole-3-methanol
	5-(3,5-Dichlorophenylthio)-1-isopropyl-4-(3-methoxybenzyl)-1H-pyrazole-3-methanol
	5-(3,5-Dichlorophenylthio)-4-(3,4-difluorobenzyl)-1-isopropyl-1H-pyrazole-3-methanol
	5-(3,5-Dichlorophenylthio)-4-ethyl-1-isopropyl-1H-pyrazole-3-methanol
	Carbamic acid [5-(3,5-dichlorophenylthio)-4-ethyl-1-isopropyl-1H-pyrazol-3-yl]methyl ester
	Carbamic acid [5-(3,5-dichlorophenylthio)-4-(hydroxymethyl)-1-isopropyl-1H-pyrazol-3-yl]methyl ester
	3-[[5-(3,5-Dichlorophenylthio)-3-(hydroxymethyl)-1-isopropyl-1H-pyrazol-4-yl]methoxymethyl]benzonitrile
	5-(3,5-Dichlorophenylthio)-4-[(2-furfuryloxy)methyl]-1-isopropyl-1H-pyrazole-3-methanol
	5-(3,5-Dichlorophenylthio)-1-isopropyl-1H-pyrazole-3,4-dimethanol

	Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-(3-methoxybenzyl)-1H-pyrazol-3-yl]methyl ester
	3-Chloro-5-[5-(hydroxymethyl)-2-isopropyl-4-[(4-pyridyl)methyl]-2H-pyrazol-3-ylthio]benzonitrile
	Carbamic acid [5-(3-chloro-5-cyanophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester
	5-(3-Chlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol

The useful activity of the compounds of formula I for the treatment of diseases mediated by the human immunodeficiency virus (HIV) can be demonstrated with the following assay methods.

HIV-1 reverse transcriptase assay: Inhibitor IC₅₀ determination.

5 HIV-1 RT assay was carried out in 96-well Millipore filtermat NOB50 plates using purified recombinant enzyme and a poly(rA)/oligo(dT)₁₆ template-primer in a total volume of 50 µL. The assay constituents were 50 mM Tris/HCl, 50 mM NaCl, 1 mM EDTA, 6 mM MgCl₂, 5 µM dTTP, 0.1 µCi [³H] dTTP, 5 µg/ml poly (rA) pre annealed to 2.5 µg/ml oligo (dT)₁₆ and a range of inhibitor concentrations in a final concentration of 10% DMSO. Reactions were initiated by adding 5 nM HIV-1 RT and after incubation at 37°C for 30 min, they were stopped by the addition of 50 µl ice cold 20%TCA and allowed to precipitate at 4°C for 30 min. The precipitates were collected by applying vacuum to the plate and sequentially washing with 2 x 200 µl of 10% TCA and 2 x 200 µl 70% ethanol. Finally the plates were dried and radioactivity counted in a Wallac Microbeta 1450 after 15 the addition of 15 µl scintillation fluid per well. IC₅₀'s were calculated by plotting % inhibition versus log₁₀ inhibitor concentrations.

Antiviral assay method

Anti-HIV antiviral activity was assessed using an adaptation of the method of Pauwels et al. {Pauwels et al., 1988, J Virol Methods 20:309-321}. The method is based on 20 the ability of compounds to protect HIV-infected T lymphoblastoid cells (MT4 cells) from cell-death mediated by the infection. The endpoint of the assay was calculated as the concentration of compound at which the cell viability of the culture was preserved by 50% ('50% inhibitory concentration', IC₅₀). The cell viability of a culture was determined by the uptake of soluble, yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 25 (MTT) and its reduction to a purple insoluble formazan salt. After solubilization, spectrophotometric methods were employed to measure the amount of formazan product.

MT4 cells were prepared to be in logarithmic-phase growth and a total of 2 x 10⁶ cells infected with the HXB2-strain of HIV at a multiplicity of 0.0001 infectious units of virus per cell in a total volume of between 200-500 microlitres. The cells were incubated 30 with virus for one h at 37°C before removal of virus. The cells are then washed in 0.01 M phosphate buffered saline, pH 7.2 before being resuspended in culture medium for incubation in culture with serial dilutions of test compound. The culture medium used was RPMI 1640 without phenol red, supplemented with penicillin, streptomycin, L-glutamine and 10% fetal calf serum (GM10).

Test compounds were prepared as 2 mM solutions in dimethyl sulphoxide (DMSO). Four replicate, serial 2-fold dilutions in GM10 were then prepared and 50 microlitres amounts placed in 96-well plates over a final nanomolar concentration range of 625 – 1.22. Fifty microlitres GM10 and 3.5×10^4 infected cells were then added to each well. Control
 5 cultures containing no cells (blank), uninfected cells (100% viability; 4 replicates) and infected cells without compound (total virus-mediated cell death; 4 replicates) were also prepared. The cultures were then incubated at 37 °C in a humidified atmosphere of 5% CO₂ in air for 5 d.

A fresh solution of 5 mg/mL MTT was prepared in 0.01 M phosphate buffered saline,
 10 pH 7.2 and 20 microlitres added to each culture. The cultures were further incubated as before for 2 h. They were then mixed by pipetting up and down and 170 microlitres of Triton X-100 in acidified isopropanol (10% v/v Triton X-100 in 1:250 mixture of concentrated HCl in isopropanol). When the formazan deposit was fully solubilized by
 15 further mixing, the absorbance (OD) of the cultures was measured at 540nm and 690nm wavelength (690nm readings were used as blanks for artefacts between wells). The percent protection for each treated culture can be calculated from the equation:









% Protection =










(OD drug-treated cultures) – (OD untreated virus control cultures)


————— x 100%

20 (OD uninfected cultures) – (OD untreated virus control cultures)

In the assay, compounds of the formula I range in IC₅₀ activity from about 0.5 to about 5000 nM, with preferred compounds having a range of about 0.5 to about 750 nM, more preferably about 0.5 to 300 nM, and most preferably about 0.5 to 50 nM.


Structure	RT IC ₅₀ /nM	HIV IC ₅₀ /nM
	62	1.3
	32	1
	714	7
	44	1
	7921	-
	525	-
	99	13
	183	30

	434	93
	206	6
	211	30
	31	3
	518	-
	51	38
	123	-
	61	-
	6304	-

	250	-
---	-----	---

The processes for the preparation of compounds of formula I, their ethers and pharmaceutically acceptable salts as well as their compounds, whenever prepared by these
5 processes are also an object of the present invention.

The compounds of the present invention can be prepared in accordance with known methods, e.g. as shown in the following schemes:

Reaction scheme 1:

wherein R^1 and R^2 are as described in formula I, A signifies a group aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methyl or substituted heterocyclyl-methyl as described in formula I, R^4 is heterocyclyl or substituted heterocyclyl as defined for compounds of formula I and Hal represents chlorine, bromine or iodine.

In reaction scheme 1, step 1 is carried out in that a hydrazine derivative of formula II is reacted with compound of formula III (commercially available from Aldrich or Fluka) to obtain the pyrazole derivative of formula IV. The reaction is conveniently carried out in the presence of a carboxylic acid, for example acetic acid, in an appropriate solvent such as halogenated hydrocarbons (e.g. dichloromethane or trichloromethane) or hydrocarbons (e.g. cyclohexane, methyl cyclohexane, decaline, benzene, toluene, o-xylene, m-xylene or p-xylene), preferably toluene. Further, the reaction is carried out at a reaction temperature from room temperature to boiling temperature of the reaction mixture, preferably at a reaction temperature between about 50°C and about 150°C.

In step 2 of the reaction scheme, the 5-hydroxy position of pyrazole derivative of formula IV is chlorinated and formylated with a suitable agent. A suitable agent is for example (COCl)₂, SOCl₂ or POCl₃ in combination with N,N-dimethylformamide or N-methylformanilide to obtain the 5-chloro-4-formylpyrazole derivative of formula V. The reaction is conveniently carried out under an inert atmosphere such as nitrogen or argon atmosphere at a reaction temperature from room temperature to boiling temperature of the reaction mixture. Preferably, the reaction is carried out in the presence of POCl₃ and N,N-dimethylformamide at a reaction temperature between about 50°C and about 120°C, more preferred at a reaction temperature between about 90°C and about 110°C.

In step 3 of the reaction scheme, compound of formula V is reacted with a thiole derivative of formula VI (agents are commercially available or can be synthesized according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons), to obtain the pyrazole derivative of formula VII. The reaction is carried out in an appropriate solvent in the presence of a base such as n-BuLi, sodium hydride, trialkylamine (e.g. trimethylamine or triethylamine), potassium carbonate, sodium carbonate, magnesium carbonate, calcium carbonate, preferably potassium carbonate. Further, the reaction is conveniently carried out under an inert atmosphere such as nitrogen or argon atmosphere at a reaction temperature from 0°C to boiling temperature of the reaction mixture, preferably at a reaction temperature between about 10°C and about 180°C, more preferred at a reaction temperature from 70°C to 130°C of the reaction mixture. Appropriate solvents for the reaction are THF or polar aprotic solvents such as dimethylsulfoxide (DMSO), dimethylacetamide or N,N-dimethylformamide (DMF), preferably DMF.

The thiole derivative of formula VI can as well be derivatised for example in the following way: Commercially available bromo-substituted thiole derivative of formula VI is converted to the corresponding cyano-substituted thiole derivative according to methods known in the art for example textbooks about organic chemistry e.g. from J.

March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

In step 4 of the reaction scheme the pyrazole of formula VII is derivatised with a Grignard reagent R^4MgHal of formula VIII, wherein R^4 is heterocyclyl or substituted heterocyclyl as defined for compounds of formula I and Hal represents chlorine, bromine or iodine, preferably chlorine (commercially available or synthesised according to textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed. John Wiley and Sons) to obtain the corresponding substituted hydroxy-methyl-pyrazole derivative of formula IX. The derivatisation reaction is conveniently carried out in an inert solvent for example ethers such as tetrahydrofuran, diethyl ether, dibutyl ether, dioxane, diglyme or a mixture of the mentioned solvents, preferably tetrahydrofuran at a reaction temperature between about -10°C and about 60°C, preferably at a reaction temperature between about 0°C and about 40°C, more preferred at room temperature. In general, the derivatisation reaction can also be carried out as described in textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons.

In step 5 of the reaction scheme, the substituted hydroxy-methyl group of compound of formula IX is reduced to the corresponding methylene group, to obtain the compound of formula X. The reaction is conveniently carried out in the presence of trialkylsilane such as trimethylsilane, triethylsilane or tripropylsilane, preferably triethylsilane, dissolved in mineral acids such as trifluoroacetic acid (TFA) or in Lewis acids such as $SnCl_4$ (described in D. L. Comins et al., Tet. Lett., 1986, 27, 1869). Further, the reaction is carried out at a reaction temperature from 0°C to 80°C, preferably at a reaction temperature between about 5°C and about 50°C.

The reduction reaction can also be carried in the presence P_2I_4 as described in EP 0627423.

The reduction reaction of the substituted hydroxy methyl group of compound of formula IX can also be carried in the presence of NaI, $(CH_3)_3SiCl$ and HBr or as described in textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). When the hydroxy group is converted to a leaving group such as a mesylate or sulphonate, preferably a mesylate, the reaction can then be carried out in the presence of Zn and acetic acid (described in J. E. Lynch et al., J. Org. Chem., 1997, 62, 9223-9228).

In step 6 of the reaction scheme, the carboxylic ester group of compound of formula X is reduced to a hydroxy-methyl group, to obtain the corresponding compound of formula Ia. The reaction is carried out in the presence of a reducing agent such as lithium aluminium hydride. Preferably, the reaction is carried out by treating the compound of formula X under nitrogen atmosphere with a reducing agent for example LiAlH_4 , LiBH_4 , $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$, iso- Bu_2AlH or Vitride®, in an inert solvent such as ethers for example anhydrous diethyl ether, THF or dioxane at a reaction temperature from 0°C to room temperature. More preferred, the reaction is carried out with LiAlH_4 and ethers.

In step 7 of the reaction scheme, the hydroxy-methyl function of the pyrazole derivative of formula Ia is derivatised to the primary carbamate of formula Ib, e.g. using trichloroacetyl isocyanate of formula XI. The pyrazole derivative of formula Ia is conveniently dissolved in a suitable organic solvent such as dichloromethane or chloroform and the reagent trichloroacetyl isocyanate of formula XI is added at a reaction temperature from -10°C to 5°C. The work up involves use of bases such as sodium or potassium carbonate followed by purification using standard procedures. Other methods known in the art can effect this transformation, such as chlorosulfonyl isocyanate or trimethylsilyl isocyanate.

The amino-function of compound of formula Ib can also be mono or dialkylated to obtain the corresponding C_{1-4} -alkyl substituted amino function. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

In step 8 of the reaction scheme, the hydroxy-methyl function of the pyrazole derivative of formula Ia is derivatised to the corresponding azido of formula Ic, e.g. using sodium azide or diphenylphosphoryl azide in standard procedures according to methods known from textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons.

In step 9 of the reaction scheme, compound Ic is reduced to a corresponding primary amine of formula Id. The reduction reaction to the primary amine of formula Id is carried out by hydrogenation with standard catalysts such as 10% palladium on carbon in suitable solvents, such as ethyl acetate, methanol or ethanol, or with a trialkyl or aryl phosphine (e.g. trimethylphosphine, triethylphosphine or triphenylphosphine).

In step 10, 11 and 12 of the reaction scheme, the primary amine function of compound of formula Id is acylated, sulfonylated or reacted with isocyanates, to obtain the corresponding compounds of formula Ie, If and Ig according to methods known from

textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons. These are standard reactions of which there are many combinations of reagents. Acylation (step 10) may be achieved via acid chlorides or other activated carbonyl compounds such as activated

5 carboxylic acids, for example with C₁₋₄-alkyl chloroformate (e.g. methyl chloroformate) in the presence of an amine (e.g. trimethylamine or triethylamine, preferably triethylamine) and dichloromethane as solvent at room temperature. The sulfonylation reaction (step 11) is carried out via sulfonyl chlorides (e.g. C₁₋₄-alkyl sulfonyl chlorides such as methyl sulfonyl chloride) using a base such as triethylamine, N-methyl morpholine or N-ethyl

10 morpholine, and dichloromethane as solvent at room temperature. The reaction with isocyanates (step 12) is carried out in that compound of formula Id is reacted with trichloroacetyl isocyanate of formula XI as described for step 7, to obtain a compound of formula Ig. The amino-function of compound of formula Ig can also be mono or dialkylated to obtain the corresponding C₁₋₄-alkyl substituted amino function. The


15 reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

The reactions according to steps 10, 11 and 12 may be conducted in suitable solvents known to those skilled in the art, for example, dichloromethane, chloroform, dioxane,

20 dimethylformamide or tetrahydrofuran.

The NH-function of compounds of formula Ie, If or Ig can be alkylated with C₁₋₄-alkyl, preferably methyl or ethyl. The alkylation reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley

25 & Sons).

Reaction scheme 2:

wherein R^1 and R^2 are as described in formula I and wherein A signifies a group A signifies a group aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl as described in formula I.

In reaction scheme 2, step 1 is carried out in that the aldehyde of formula VII is reduced in the presence of a reducing agent to obtain the corresponding hydroxy-methyl derivative of formula XII. Reducing agents conveniently used for the reaction are preferably sodium borohydride or other reducing agents such as lithium borohydride, sodium triacetoxyborohydride, hydrogen over a catalyst or reducing agents known in the art applied according to known methods described in textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed. John Wiley and Sons. The reduction reaction is conveniently carried out

in an organic solvent for example alcoholic solvents such as methanol, ethanol, propanol, butanol, octanol or cyclohexanol, preferably methanol or ethanol or ethers such as tetrahydrofuran, diethyl ether, dibutyl ether, dioxane or diglyme, preferably tetrahydrofuran or a mixture of the mentioned solvents such as methanol and
5 tetrahydrofuran or ethanol and tetrahydrofuran. The reaction is carried out at a reaction temperature between about -10°C and about 60°C, preferably at room temperature. The reduction reaction can also be carried out as described in textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons.

10 In step 2 of the reaction scheme, the hydroxy-methyl function of compound of formula XII is converted to the corresponding bromo-methyl derivative of formula XIII according to standard procedures according to methods known from textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons. A possible method for the
15 preparation of a bromide derivative of formula XIII is by using tetrabromomethane in the presence of triphenylphosphine in dichloromethane, at room temperature.

In step 3 of the reaction scheme, the bromide of formula XIII is reacted with a heterocyclyl-methanol compound of formula XIV to obtain the corresponding pyrazole derivative of formula XV. The reaction is conveniently carried out according to methods
20 known from textbooks on organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed. John Wiley and Sons). The reaction is for example carried out in the presence of a base such as sodium hydride, lithium hydride, potassium carbonate or triethylamine in an appropriate organic solvent such as tetrahydrofuran (THF) or polar aprotic solvents like dimethylsulfoxide (DMSO),
25 N,N-dimethylacetamide or N,N-dimethylformamide (DMF), preferably DMF or THF, at a reaction temperature between about -10°C and about 60°C, preferably at room temperature.

In step 4 of the reaction scheme, the carboxylic ethyl function of compound of formula XV is reduced with an appropriate reducing agent to obtain the corresponding
30 hydroxy-methyl derivative of formula Ih. The reaction is conveniently carried out under nitrogen atmosphere with a reducing agent for example LiAlH₄, LiBH₄, BH₃*S(CH₃)₂, iso-Bu₂AlH or Vitride®, in an inert solvent such as ethers for example anhydrous diethyl ether, THF or dioxane at a reaction temperature from 0°C to room temperature. Preferably, the reaction is carried out with LiAlH₄ in an ether such as THF. Subsequently a solution of
35 ammonium chloride is added to yield to a compound of the formula Ih. After the reaction, the product is worked up in a manner known in the art for example extracted with ethyl


acetate, dried over anhydrous magnesium sulphate and finally the organic solvent is evaporated.

In step 5 of the reaction scheme, the hydroxy-methyl derivative of formula Ih is derivatised to the primary carbamate of formula Ii. The reaction is carried out with
5 trichloroacetyl isocyanate of formula XI as described for reaction scheme 1 (step 7).

The hydroxy function of compound of formula Ih can also be acylated to obtain the corresponding compound of formula I wherein $m=0$, $X=O$ and $Z=C_{1-4}$ -alkyl. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and
10 Structure", 4th ed. John Wiley & Sons).

The hydroxy function of compound of formula Ih can also be transformed to obtain the corresponding compound of formula I wherein $m=0$, $X=O$ and $Z=C_{1-4}$ -alkoxy. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions,
15 Mechanisms, and Structure", 4th ed. John Wiley & Sons). The amino-function of compound of formula Ii can also be mono or dialkylated to obtain the corresponding C_{1-4} -alkyl substituted amino function. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

20 Compound of formula Ih is reacted according the methods described in reaction scheme 1 (step 8-12) and thereby the corresponding pyrazole derivatives are obtained, wherein A signifies heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl as described in formula I.

Reaction scheme 3:

wherein R^1 , R^2 and A are as described in formula I.

- 5 In reaction scheme 3, step 1 is carried out in that the hydroxymethyl derivative of formula Ia is chlorinated to give the corresponding chloromethyl derivative of formula XVI according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). The reaction can for example be carried out in the presence of
- 10 $SOCl_2$ as chlorinating agent. The hydroxymethyl derivative of formula Ia can also be converted to the corresponding iodide, bromide, mesylate or tosylate according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons)
- 15 In step 2 of the reaction scheme, the chloromethyl derivative of formula XVI is reacted with potassium cyanide in the presence of potassium iodide and DMF, to give the corresponding cyanomethyl derivative of formula Ij, according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). The


reaction can as well be carried out with alternative solvents such as DMSO, acetone, acetonitrile, ethanol (and other alcohols)/water mixtures. An optional additive is 18-crown-6

In step 3 of the reaction scheme, the cyano group of compound of formula Ij is
5 hydrolysed to obtain the corresponding carboxylic acid of formula Ik according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). The reaction is for example carried out in the presence of potassium hydroxide and 1-methoxy-2-hydroxy-ethane. The reaction can as well be carried out in sodium
10 hydroxide or mineral acids, and alternative solvents are methanol, ethanol, water or mixtures thereof.

In step 4 of the reaction scheme, the carboxylic acid group of formula Ik is reduced to obtain the corresponding alcohol of formula Il. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992),
15 "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons), for example in the presence of a reducing agent such as BH_3 , $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$ or LiAlH_4 (all commercially available) in an inert solvent such as ethers for example anhydrous diethyl ether, THF or dioxane at a reaction temperature from 0°C to room temperature. More preferred, the reaction is carried out with BH_3 in the presence of ethers.

In step 5 of the reaction scheme, the carboxylic acid of formula Ik is derivatised with an amine of formula XVII to obtain the corresponding amide of formula Im according to methods known from textbooks about organic chemistry e.g. from J. March (1992),
20 "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).


The amino-function of compound of formula Im can also be alkylated to obtain the corresponding C_{1-4} -alkyl substituted amino function. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992),
25 "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

Reaction scheme 4:

wherein R^1 , R^2 and A are as described in formula I and Y signifies a leaving group.

- 5 In reaction scheme 4, step 1 is carried out in that the hydroxymethyl derivative of formula Ia is alkylated with a compound of formula XVIII, wherein Y signifies a leaving group, to obtain the corresponding ether of formula In according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). A leaving group is for example chlorine, bromine, iodine or mesylate (bromine is preferred). The reaction is for example carried out with a compound of formula XVIII in the presence of a base such as sodium hydride or potassium carbonate.

- 15 In step 2 of the reaction scheme, the ester of formula In is hydrolysed to obtain the corresponding carboxylic acid and subsequently derivatised, to obtain the corresponding amide of formula Io according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). The derivatisation reaction can be carried out for example with an amine of formula XVII or with ammonia. The amino-function of compound of formula Io can also be alkylated to obtain the corresponding C_{1-4} -alkyl substituted amino function. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).


Reaction scheme 5:

wherein R^1 , R^2 and A are as described in formula I.

- 5 In reaction scheme 5, the reaction is carried out in that the primary amine of formula Id is derivatised with caboxylic acid of formula XIX (commercially available or prepared according to methods known in the art), to obtain the corresponding amide of formula Ip. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).
- 10

The NH-function of compounds of formula Ip can be alkylated with C_{1-4} -alkyl, preferably methyl or ethyl. The alkylation reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons).

15

Reaction scheme 6:


wherein R^1 , R^2 and A are as described in formula I.

20

In reaction scheme 6, step 1 is carried out in that the carboxylic acid group of compound of formula Ik is alkylated with C_{1-4} -alkyl, preferably methyl or ethyl, to obtain compound of formula Iq. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), "Advanced Organic

Chemistry: Reactions, Mechanisms, and Structure”, 4th ed. John Wiley & Sons). In a more preferred way, the esterification is carried out via an activated acid derivative (e.g. acid chloride) and an alcohol.

5 In step 2 of the reaction scheme, the the carboxylic acid group of compound of formula Ik is alkylated with C₁₋₄-alkyl, preferably methyl or ethyl, to obtain the corresponding C₁₋₄-alkyl-carbonyl-methyl substituted pyrazole compound of formula Ir. The reaction is carried out according to methods known from textbooks about organic chemistry e.g. from J. March (1992), “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure”, 4th ed. John Wiley & Sons).

Reaction scheme 7:

wherein R^1 and R^2 are as described in formula I.

- 5 In reaction scheme 7, step 1 is carried out in that the aldehyde function of compound of formula VII is reacted via a Wittig-Horner reaction with dialkyl phosphonate of formula $(\text{EtO})_2\text{P}(=\text{O})(\text{CH}_3)$. The reaction is carried out similar the method described in the literature, for example in the presence of a strong base such as $n\text{-BuLi}$ or preferably sodium hydride in an organic solvent for example anhydrous ethers

such as diethyl ether, dibutyl ether, dioxane, preferably anhydrous tetrahydrofuran under inert atmosphere such as nitrogen or argon atmosphere at a reaction temperature from 0°C to 80°C, preferably at a reaction temperature between about 5°C and about 50°C. Optionally, olefinic compound of formula Ic can be obtained through other coupling reactions for example the Wittig reaction.

The Wittig-Horner reaction can also be carried out with dialkyl phosphonates of formula $(\text{EtO})_2\text{P}(=\text{O})-(\text{C}_{1-11}\text{alkyl})$ (commercially available or synthesized according to known methods in the art) to a corresponding olefinic compound of formula XX.

In the second step of the reaction, the olefinic group of compound of formula XX is hydrogenated to the corresponding compound of formula XXI. The reaction is carried out similar to methods described in the literature, for example under hydrogen in the presence of a hydrogenation catalyst in an appropriate solvent at a reaction temperature from 0°C to 80°C, preferably at a reaction temperature between about 5°C and about 50°C. The hydrogen pressure can be between about 0atm and about 100atm, preferably between about 0atm and about 50atm and most preferred between about 0atm and about 20atm. The hydrogenation catalyst used for this reaction can be one of the commonly known catalysts such as noble metals (e.g. Pt, Pd or Rh) on supporting materials such as activated carbon or Al_2O_3 , or generally as described in textbooks about organic chemistry e.g. J. March (1992), "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 4th ed. John Wiley & Sons). Preferred hydrogenation catalysts are Pd on activated carbon or Raney-Nickel. Appropriate solvents for the hydrogenation reaction are organic solvent such as alcohols (e.g. methanol, ethanol, propanol, butanol, octanol or cyclohexanol), ethers (e.g. tetrahydrofuran, diethyl ether, dibutyl ether or dioxane), ketones (e.g. acetone, butanone or cyclohexanone), polar aprotic solvents such as dimethylsulfoxide (DMSO) or dimethylacetamide N, esters (e.g. ethyl acetate), halogenated hydrocarbons (e.g. dichloromethane or trichloromethane), hydrocarbons (e.g. cyclohexane, methyl cyclohexane, decaline, benzene, toluene, o-xylene, m-xylene or p-xylene) or a mixtures of the mentioned solvents. Preferred solvents are ester, most preferred solvent is ethyl acetate.

In step 3 of the reaction scheme, the carboxylic ester group of compound of formula XXI is reduced to a hydroxy-methyl group, to obtain the corresponding compound of formula Is. The reaction is carried out in the presence of a reducing agent such as lithium aluminium hydride. Preferably, the reaction is carried out by treating the compound of formula XXI under nitrogen atmosphere with a reducing agent for example LiAlH_4 , LiBH_4 , $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$, iso- Bu_2AlH or Vitride®, in an inert solvent such as ethers for example anhydrous diethyl ether, THF or dioxane at a reaction temperature from 0°C to room temperature. More preferred, the reaction is carried out with LiAlH_4 and ethers.

In step 4 of the reaction scheme, the hydroxy-methyl function of the pyrazole derivative of formula Ia is derivatised to the primary carbamate of formula Ib, e.g. using trichloroacetyl isocyanate of formula XI. The pyrazole derivative of formula Ia is conveniently dissolved in a suitable organic solvent such as dichloromethane or chloroform and the reagent trichloroacetyl isocyanate of formula XI is added at a reaction temperature from -10°C to 5°C . The work up involves use of bases such as sodium or potassium carbonate followed by purification using standard procedures. Other methods known in the art can effect this transformation, such as chlorosulfonyl isocyanate or trimethylsilyl isocyanate.

The compounds of the present invention and pharmaceutical compositions containing the same are useful as chemotherapeutic agents, inhibitors of viral replication and modulators of the immune system, and can be used for the treatment of diseases mediated by the human immunodeficiency virus (HIV) other viral diseases such as retroviral infections (either alone or in combination with other antiviral agents such as interferon or derivatives thereof, such as conjugates with polyethylene glycol).

They can be used alone, or in combination with other therapeutically active agents, for example, an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an antibiotic, an anti-parasitic agent, an anti-inflammatory agent, an anti-fungal agent and/or an anti-vascular hyperproliferation agent.

It will be understood that references herein to treatment extend to prophylaxis as well as to treatment of existing conditions. Treatment of a disease or condition, as used herein, also includes preventing, inhibiting, regressing, reversing, alleviating or relieving the disease or condition, or the clinical symptoms thereof. The term "subject" as used herein refers to animals, including humans and other mammals.

In the present specification "comprise" means "includes " and "comprising" means "including ".

The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.

The pyrazole derivatives provided by the present invention can be used together with a therapeutically inert carrier as medicaments in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered enterally, such as orally, in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, or nasally, e.g. in the form of nasal sprays. They can also be administered rectally, e.g. in the form of suppositories, or parenterally, (e.g. intramuscularly, intravenously, or subcutaneously), for example, in the form of injection solutions.

For the manufacture of pharmaceutical preparations the pyrazole derivatives can be formulated with therapeutically inert, inorganic or organic carriers.

Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules.

Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like.

Suitable carriers for the manufacture of injection solutions are, for example, water, saline, alcohols, polyols, glycerine, vegetable oils and the like. Natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like are suitable carriers for the manufacture of suppositories. The pharmaceutical preparations of the present invention may also be provided as sustained release formulations or other appropriate formulations.

The pharmaceutical preparations can also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavourants, salts for adjustment of the osmotic pressure, buffers, masking agents or antioxidants.

The pharmaceutical preparations may also contain other therapeutically active agents such as those mentioned above.

The pyrazole derivatives provided by the invention in the treatment of an immune mediated condition or disease, a viral disease, a bacterial disease, a parasitic disease, an inflammatory disease, a hyperproliferative vascular disease, a tumor, or cancer.

The dosage can vary within wide limits and will, of course, be adjusted to the individual requirements in each particular case.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day in monotherapy and/or in combination therapy are commonly administered from about 1 to 5 times per day. A typical preparation will contain from about 5% to 95% active compound (w/w). The daily dosage can be administered as a single dosage or in divided dosages.

The pyrazole derivatives provided by the present invention or the medicaments thereof may be for use in monotherapy and/or combination therapy, i.e. the treatment may be in conjunction with the administration of one or more additional therapeutically active substance(s). When the treatment is combination therapy, such administration may be concurrent or sequential with respect to that of the pyrazole derivatives of the present invention. Thus, concurrent administration, as used herein, includes administration of the agents in conjunction or combination, together, or before or after each other.

With regard to the starting materials that are known compounds some of these may be purchased from commercial suppliers. Other starting materials that are known and their analogues can be prepared by methods well known in the art. Examples of

compounds available from commercial suppliers, and citations to the synthesis of other compounds and their analogues are provided in the following:

The described NMR spectra were recorded on a Bruker DRX 400 MHz spectrometer with the probe temperature set at 300 K.

5 The mass spectra indicated by “(M+; EI)”, were recorded under electron impact conditions (EI), on a THERMOQUEST MAT95 S with a source temperature of 200°C. Other mass spectra were recorded under electrospray ionization spectra (ESI) conditions, on one of the following machines:

10 a) THERMOQUEST SSQ 7000 [Solvent 0.085% TFA in 90% Acetonitrile/water; flow rate 100 microliters/minute; capillary 250°C; spray voltage 5KV; sheath gas 80 psi], or

 b) LC-MS system (liquid chromatograph coupled to mass spectrum)
THERMOQUEST TSQ 7000 ELECTROSPRAY or MICROMASS PLATFORM
ELECTROSPRAY [Solvent 0.1% TFA in water or 0.085% TFA in 90% acetonitrile/ water
or 0.085% TFA in acetonitrile].

15

In the following examples the abbreviations used have the following significations:

min	minute(s)
h	hour(s)
d	day(s)
20 Vitride®	sodium bis (2-methoxyethoxy)aluminum hydride (Fluka)

The following examples illustrate the present invention:

Example 15-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol

A solution containing 0.4ml of lithium aluminium hydride (1M solution in THF) in 2ml of anhydrous tetrahydrofuran at 0°C under nitrogen was treated dropwise with a solution of 154mg of 5-(3,5-Dichloro-phenylsulfanyl)-1-isopropyl-4-pyridin-4-ylmethyl-1H-pyrazole-3-carboxylic acid ethyl ester in 2ml of anhydrous tetrahydrofuran. The mixture was stirred at 0°C for 0.5 h then treated with 0.012ml of water, 0.012ml of 2N sodium hydroxide solution and then 0.018ml of water. The mixture was stirred for 0.5 h at 0°C; the mixture was filtered and then the solvent removed. The residue was purified by flash chromatography on silica gel using dichloromethane / methanol (1:19) for the elution to give 90mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol as a white gum. Mass spectrum (ESI) m/z 408 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 3.90 (s, 2H), 4.55 (d, 2H), 4.72 (m, 1H), 5.30 (t, 1H), 6.85 (s, 2H), 7.15 (d, 2H), 7.35 (s, 1H), 8.30 (d, 2H).

The starting material 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester was prepared as follows:

(A) A solution containing 15.01g of tert-butyl carbazate in 80 ml of acetone was stirred at 60°C for 2h. The mixture was evaporated under reduced pressure to give 19.25g of N'-isopropylidene-hydrazinecarboxylic acid tert-butyl ester as a white solid which was used without further purification.

(B) A solution containing 19.25g of N'-isopropylidene-hydrazinecarboxylic acid tert-butyl ester in 100 ml of methanol was treated with 12g of 5% Pt / C catalyst. The mixture was then hydrogenated at atmospheric pressure for 15 h. The mixture was then filtered through hyflo and solvent removed to give 16.77g of N'-isopropyl-hydrazinecarboxylic acid tert-butyl ester as a colourless oil which was used without further purification.

(C) A solution containing 15.6g of N'-isopropyl-hydrazinecarboxylic acid tert-butyl ester in 100ml of 4N HCl in ethyl acetate was stirred at room temperature for 15 h. The mixture was then evaporated to give 13g of isopropylhydrazine dihydrochloride which was used without further purification.

(D) A solution containing 29g of isopropylhydrazine dihydrochloride in 150ml of water was added dropwise to a stirred solution of 41.7g of diethyl oxalacetate, sodium salt in 300ml of acetic acid and 150ml of toluene. The mixture was heated at 140°C for 5 h. The mixture was left to cool to room temperature and then the solvent was evaporated under

reduced pressure and the residue azeotroped with toluene. The residue was partitioned between dichloromethane and water. The dichloromethane extract was washed with brine, dried over anhydrous magnesium sulphate, filtered and evaporated under reduced pressure. The residue was triturated with diethyl ether to give a white solid which was
5 filtered then washed three times with cold diethyl ether and dried to give 11.1g of 5-hydroxy-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a white solid which was used without further purification.

(E) 8g of 5-hydroxy-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester was added portionwise to a preformed mixture of 3.44ml of dimethylformamide and 94ml of
10 phosphorus oxychloride at 0°C under nitrogen. The mixture was then heated at 100°C for 20 h. The mixture was evaporated under reduced pressure, the residue poured into ice-cold saturated sodium hydrogen carbonate and then extracted three times with dichloromethane. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated to give 9.1g of 5-chloro-4-formyl-
15 1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a light brown solid which was used without further purification. Mass spectrum (ESI) m/z 245 $[M+H]^+$.

(F) A solution containing 6g of 5-chloro-4-formyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester in 10ml of anhydrous dimethyl formamide was treated at room temperature with 5.28g of 3,5-dichlorothiophenol and 4.07g of potassium carbonate. The
20 mixture was then heated at 60°C for 1h before being left to cool to room temperature. The solvent removed under reduced pressure and the residue partitioned between dichloromethane and water. The organic extract was washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using diethyl ether / petroleum ether (1:4 to 1:3) for the
25 elution to give 8.53g of 5-(3,5-dichlorophenylthio)-4-formyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a yellow oil. Mass spectrum (ESI) m/z 387 $[M+H]^+$.

(G) 582mg of 4-Bromopyridine hydrochloride was treated with a 5% sodium carbonate solution then extracted three times with anhydrous diethyl ether. The combined
30 extracts were then dried over anhydrous magnesium sulphate, filtered and evaporated to give a colourless oil. The colourless oil was dissolved in 3 ml of anhydrous tetrahydrofuran under nitrogen at room temperature and then treated with 1.5ml of isopropylmagnesium chloride (2M solution in tetrahydrofuran). The mixture was stirred at room temperature for 1.5 h and then treated with a solution of 5-(3,5-dichlorophenylsulfanyl)-4-formyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester in 3ml of anhydrous tetrahydrofuran.
35 The mixture was then stirred for 1 h. The mixture was then treated with water and extracted with dichloromethane three times. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue




was purified by flash chromatography on silica gel using ethyl acetate / petroleum ether (1:1 to 2:1) for the elution to give 690mg of 5-(3,5-dichlorophenylsulfanyl)-4-[(4-pyridyl)hydroxymethyl]-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a pale yellow oil. Mass spectrum (ESI) m/z 466 $[M+H]^+$.

- 5 (H) A solution containing 660mg of diphosphorus tetraiodide in 5ml of anhydrous toluene was heated at 80°C for 20 min under nitrogen in the dark. The mixture was then treated dropwise with a solution of 674mg of 5-(3,5-dichlorophenylthio)-4-[(4-pyridyl)hydroxymethyl]-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester in 5ml of anhydrous toluene. The mixture was stirred at 80°C for 1 h and then left to cool to room
10 temperature. The mixture was treated with 10ml of a 10% solution of sodium bisulphite and then stirred at room temperature for 1 h. The mixture was partitioned between ethyl acetate and water then extracted three times. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue
15 was purified by flash chromatography on silica gel using ethyl acetate / petroleum ether (1:1 to 2:1) for the elution to give 483mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester as a pale yellow gum. Mass spectrum (ESI) m/z 450 $[M+H]^+$.





Examples 1a-1e

- 20 The compounds shown in table 2 were prepared in a manner analogous to that described in example 1

Table 2

Example	Structure	MS (ES) (M+H) ⁺
1a		394.35
1b		376.36
1c		454.27

- 44 -

1d		437.22
1e		443 (M ⁺)
1f		413.27
1g		501.16

Example 2






5 Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester

A solution containing 100mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol in 3ml of anhydrous dichloromethane was stirred under nitrogen at 0°C while 35μl of trichloroacetyl isocyanate was added dropwise. The mixture was stirred at 0°C for 2 h. The mixture was evaporated under reduced pressure and then the residue was treated with 2ml of methanol, 1ml water and 100mg of potassium carbonate under nitrogen at 0°C. The mixture was then stirred at room temperature for 1 h. The mixture was partitioned between ethyl acetate and water then extracted with ethyl acetate three times. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using methanol/dichloromethane (1:49) for the elution to give 67mg of carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester as a white solid. Mass spectrum (ESI) m/z 451 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 3.91 (s, 2H), 4.77 (m, 1H), 5.05 (s, 2H), 6.55 (br s, 1H), 6.78 (br s, 1H), 6.79 (s, 2H), 7.08 (d, 2H), 7.39 (s, 1H), 8.30 (d, 2H).

Examples 2a-2e

The compounds shown in table 3 were prepared in a manner analogous to that described in example 2

Table 3

Example	Structure	MS (ES) (M+H) ⁺
2a		456.27
2b		419
2c		333 (M ⁺)
2d		480.40
2e		442.31

5

Example 3

Methylcarbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester

10 A solution containing 45mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol in 4ml of anhydrous dichloromethane under

nitrogen at room temperature was treated with 0.017ml of triethylamine and 0,007ml of methyl isocyanate. The mixture was stirred at room temperature for 1 h. The mixture was partitioned between ethyl acetate and water then extracted with dichloromethane three times. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using methanol / dichloromethane (0:1 to 1:49) for the elution to give 36 mg of methylcarbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester as a yellow gum. Mass spectrum (ESI) m/z 465 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 2.55 (d, 3H), 3.90 (s, 2H), 5.05 (s, 2H), 6.77 (s, 2H), 7.05 (d, 2H), 7.12 (m, 1H), 7.37 (s, 1H), 8.30 (d, 2H).

Example 4

5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine

A solution containing 120mg of 4-[3-Azidomethyl-5-(3,5-dichloro-phenylsulfanyl)-1-isopropyl-1H-pyrazol-4-ylmethyl]-pyridine in 5ml of ethyl acetate was treated with 20mg of 10% palladium on charcoal and then hydrogenated at atmospheric pressure for 2.0 h. The mixture was filtered and then the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel using methanol/dichloromethane (1:9) for the elution to give 61 mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine as a pale yellow oil. Mass spectrum (ESI) m/z 407 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 3.72 (s, 2H), 3.90 (s, 2H), 4.70 (m, 1H), 6.78 (s, 2H), 7.10 (d, 2H), 7.37 (s, 1H), 8.30 (d, 2H).

The starting material 4-[3-azidomethyl-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazol-4-ylmethyl]pyridine was prepared as follows:

(A) A solution containing 108mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol in 5ml of anhydrous dichloromethane at -78°C under nitrogen was treated with 45μl of thionyl chloride. The mixture was stirred for 1 h and left to warm to room temperature. The solvent was removed under reduced pressure and the residue was azeotroped with toluene to give 120mg of 4-[3-chloromethyl-5-(3,5-dichloro-phenylthio)-1-isopropyl-1H-pyrazol-4-ylmethyl]pyridine hydrochloride as a white solid which was used without further purification. Mass spectrum (ESI) m/z 426 [M+H]⁺.

(B) To a solution of 120mg of 4-[3-chloromethyl-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazol-4-ylmethyl]pyridine hydrochloride in 1ml of anhydrous dimethylformamide stirred at room temperature was added 85mg of sodium azide. The mixture was stirred for 1 h. The mixture was partitioned between diethyl ether and water then extracted three times. The combined extracts were reduced under reduced pressure to give 120mg of 4-[3-azidomethyl-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazol-4-ylmethyl]pyridine as a yellow oil which was used without any further purification. Mass spectrum (ESI) m/z 433 $[M+H]^+$.

10

Example 5

1-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]urea

A solution containing 41mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine in 2ml of anhydrous dichloromethane at 0°C under nitrogen was treated with 0.014ml of trichloroacetyl isocyanate. The mixture was stirred for 1.5 h. The solvent was removed under reduced pressure and then the residue treated with 2ml of methanol, 1ml of water and 100mg of potassium carbonate at 0°C. The mixture was stirred for 0.33 h and then a further 100mg of potassium carbonate was added. The mixture was stirred for 1.5 h. The mixture was partitioned between ethyl acetate and water then extracted with ethyl acetate three times. The combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using methanol/dichloromethane (1:9) for the elution to give 20mg of 1-[[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]urea as a white solid. Mass spectrum (ESI) m/z 450 $[M+H]^+$. 1H NMR (DMSO) 1.30 (d, 6H), 3.90 (s, 2H), 4.25 (d, 2H), 4.70 (m, 1H), 4.50 (br s, 1H), 6.40 (t, 1H), 6.75 (s, 2H), 7.07 (d, 2H), 7.36 (s, 1H), 8.30 (d, 2H).

30

Example 6N-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]methanesulfonamide

A solution containing 35mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine in 3ml of anhydrous dichloromethane at room temperature under nitrogen was treated with 0.024ml of triethylamine and 0.007ml of methane sulphonyl chloride. The mixture was stirred at room temperature for 0.5 h. The mixture was partitioned between dichloromethane and saturated sodium hydrogen carbonate then extracted three times. Combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using methanol/dichloromethane (1:19) for the elution to give 21mg of N-[[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]methanesulfonamide as a brown solid. Mass spectrum (ESI) m/z 485 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 2.90 (s, 3H), 3.92 (s, 2H), 4.20 (d, 2H), 4.73(m, 1H), 6.89 (s, 2H), 7.11 (d, 2H), 7.38 (s, 1H), 7.56 (t, 1H), 8.30 (d, 2H).

Example 7Methyl [[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]carbamate

A solution containing 21mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine in 2ml of dichloromethane at room temperature under nitrogen was treated with 0.014ml of triethylamine and 0.004ml of methyl chloroformate. The mixture was stirred for 1 h. The mixture was partitioned between dichloromethane and sodium hydrogen carbonate then extracted three times. Combined extracts were washed with brine then dried over anhydrous magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography on silica gel using methanol/dichloromethane (1:19) for the elution to give 15mg of methyl [[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]carbamate as a yellow solid. Mass spectrum (ESI) m/z 485 [M+H]⁺. ¹H NMR (DMSO) 1.30 (d, 6H), 3.45 (s, 3H), 3.90 (s, 2H), 4.28 (d, 2H), 4.75 (m, 1H), 6.80 (s, 2H), 7.13 (d, 2H), 7.36 (s, 1H), 7.65 (br t, 1H), 8.30 (d, 2H).

Example 85-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazole-3-methanol

To a solution of lithium aluminium hydride (0.2ml of 1M solution in
5 tetrahydrofuran) in tetrahydrofuran at 0°C was added a solution of 80mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[4-(pyridyl)methoxymethyl]-1H-pyrazole-3-carboxylic acid ethyl ester dropwise. The mixture was stirred at 0°C for 0.5h before water (0.007ml), 2M sodium hydroxide solution (0.007ml) then further water (0.011ml) were added. The mixture was filtered and the solvent was removed. The residue was purified by
10 flash chromatography on silica gel using methanol/dichloromethane for the elution to give 33mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazole-3-methanol as a colourless gum. Mass spectrum (ES) m/z 438 $[M]^+$. 1H NMR (DMSO- d_6) 1.30 (d, 6H), 4.50 (s, 2H), 4.55 (s, 2H), 4.58 (br s, 2H), 4.80 (m, 1H), 5.18 (br s, 1H), 7.08 (m, 2H), 7.18 (d, 2H), 7.45 (m, 1H), 8.45 (d, 2H).

15 The starting material 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[4-(pyridyl)methoxymethyl]-1H-pyrazole-3-carboxylic acid ethyl ester was prepared as follows:

(A) To a solution of 530mg of 5-(3,5-dichlorophenylthio)-4-formyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester in methanol (5ml) at 0°C was added 52mg of
20 sodium borohydride and the mixture was stirred at 0°C for 15 min. Water was added and the mixture was extracted with ethyl acetate (x3). The combined extracts were dried over magnesium sulphate, filtered and evaporated to leave 504mg of 5-(3,5-dichlorophenylthio)-4-hydroxymethyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a colourless oil. Mass spectrum (ES) m/z 389 $[M+H]^+$.

25 (B) To a solution of 504mg 5-(3,5-dichlorophenylthio)-4-hydroxymethyl-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester in 5 ml of dichloromethane was added 375mg of triphenylphosphine and 474mg of carbon tetrabromide. The reaction mixture was stirred overnight. The solvent was removed and the residue was purified by flash chromatography on silica gel using diethyl ether/iso-hexane for the elution to give 367mg
30 of 4-bromomethyl-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazole-3-carboxylic acid ethyl ester as a colourless gum. Mass spectrum (ES) m/z 451 $[M+H]^+$.



To a solution of 55mg of 4-(hydroxymethyl)pyridine in DMF at 0°C was added 20mg sodium hydride (60% in oil). To the mixture was added dropwise a solution of 229mg of 4-bromomethyl-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazole-3-

carboxylic acid ethyl ester in 2ml of N,N-dimethylformamide. After 15 min water was added and the mixture was extracted with dichloromethane (x3). The combined extracts were dried over magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography using ethyl acetate/iso-hexane for the elution to give 80mg of 5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(pyridyl)methoxymethyl]-1H-pyrazole-3-carboxylic acid ethyl ester as a colourless gum. Mass spectrum (ES) m/z 480 $[M]^+$.

Examples 8a

The compound shown in table 5 were prepared in a manner analogous to that described in example 8

Table 5

Example	Structure	MS (ES) (M+H) ⁺
8a		462(M ⁺)
8b		427.35

Example 9

Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazol-3-yl]methyl ester


To a solution of 20mg of 5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazole-3-methanol in 1ml of dichloromethane at 0°C was added 11mg of trichloroacetyl isocyanate. The mixture was stirred for 2h at 0°C then the solvent was removed. The residue was dissolved in 2ml of methanol and 1ml of water, 100mg of potassium carbonate added, and the mixture stirred at room temperature for 1h. The mixture was partitioned between ethyl acetate and water. The combined extracts were dried over magnesium sulphate, filtered and evaporated. The residue was purified by flash chromatography using methanol/dichloromethane for the elution to give 12mg of carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazol-3-yl]methyl ester as a white solid. Mass spectrum (ES) m/z 481 $[M]^+$. ¹H NMR

- 51 -

(DMSO-d₆) 1.25 (d, 6H), 4.50 (s, 2H), 4.52 (s, 2H), 4.80 (m, 1H), 5.05 (s, 2H), 6.55 (br s, 1H), 6.75 (br s, 1H), 7.08 (m, 2H), 7.16 (d, 2H) 7.45 (m, 1H), 8.43 (d, 2H).

Claims

1. Compounds of formula I



5

wherein

R¹ is alkyl or substituted alkyl;

R² is aryl or substituted aryl;

10 R³ is hydroxy, amino, azido, hydroxy-C₁₋₄-alkyl, C₁₋₄-alkyl-sulfonyl-amino or a group of the formula -X-C(=O)-Z,

wherein X represents NR^{''''}, O or a single bond; wherein R^{''''} is hydrogen or C₁₋₄-alkyl, and

wherein Z is C₁₋₄-alkyl, C₁₋₄-alkoxy or NR^{''}R^{'''}; wherein R^{''}, R^{'''} are independently of each other hydrogen or C₁₋₄-alkyl;

15 A signifies alkyl, substituted alkyl, aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methyl, substituted heterocyclyl-methyl, heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl;

20 ethers of compounds of formula I as well as pharmaceutically acceptable salts of the foregoing.

2. Compounds as claimed in claim 1 wherein

R¹ is C₁₋₁₂-alkyl or C₁₋₁₂-alkyl substituted with 1-6 fluorines;

R² is aryl or substituted aryl,

25 wherein substituted aryl means aryl substituted with 1-5 substituents selected from C₁₋₄-alkyl, substituted C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, fluorine, chlorine, bromine and cyano;

and wherein substituted C₁₋₄-alkyl means C₁₋₄-alkyl substituted with 1-3 substituents selected from hydroxy, C₁₋₄-alkoxy, CONH₂ and NRR',

5 wherein R and R' are independently of each other hydrogen, C₁₋₄-alkyl or -C(=O)CH₃;

R³ is hydroxy, amino, azido, hydroxy-C₁₋₄-alkyl, C₁₋₄-alkyl-sulfonyl-amino or a group of the formula -X-C(=O)-Z,

 wherein X represents NR''''', O or a single bond; wherein R''''' is hydrogen or C₁₋₄-alkyl, and

10 wherein Z is C₁₋₄-alkyl, C₁₋₄-alkoxy or NR''R'''; wherein R'', R''' are independently of each other hydrogen or C₁₋₄-alkyl;

A signifies C₁₋₁₂-alkyl, hydroxy-methyl, aryl-methyl, substituted aryl-methyl, aryl-methoxy-methyl, substituted aryl-methoxy-methyl, heterocyclyl-methyl, substituted heterocyclyl-methyl, heterocyclyl-methoxy-methyl or substituted heterocyclyl-methoxy-methyl,

 wherein substituted aryl-methyl means aryl substituted with 1-5 substituents selected from C₁₋₄-alkoxy, fluorine, chlorine and bromine, and

 wherein substituted aryl-methoxy-methyl means aryl substituted with 1-5 substituents, substituted heterocyclyl-methyl or substituted heterocyclyl-methoxy-methyl means heterocyclyl substituted with 1-4 substituents, the substituents selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, C₁₋₄-alkylamino, hydroxy, cyano, amino, mercapto, fluorine, chlorine and bromine.

25

3. Compounds as claimed in claim 1 or claim 2 wherein

R¹ is C₁₋₁₂-alkyl;

R² is phenyl or substituted phenyl,

 wherein substituted phenyl means phenyl substituted with 1-5 substituents selected from C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-alkylthio, fluorine, chlorine, bromine and cyano;

30

R³ is hydroxy, amino, azido, C₁₋₄-alkyl-sulfonyl-amino or a group of the formula -X-C(=O)-Z,

wherein X represents NR^{'''} or O; wherein R^{'''} is hydrogen or C₁₋₄-alkyl, and

wherein Z is C₁₋₄-alkyl, C₁₋₄-alkoxy or NR^{''}R^{'''}; wherein R^{''}, R^{'''} are independently of each other hydrogen or C₁₋₄-alkyl;

5 A signifies heterocyclyl-methyl, substituted heterocyclyl-methyl or heterocyclyl-methoxy-methyl,

wherein substituted heterocyclyl-methyl means heterocyclyl substituted with 1-4 substituents selected from C₁₋₄-alkyl, fluorine, chlorine and bromine.

10

4. Compounds as claimed in any one of claims 1 to 3 wherein

R¹ is C₁₋₇-alkyl;

R² is substituted phenyl,

15 wherein substituted phenyl means phenyl substituted with 1-5 substituents selected from fluorine, chlorine, bromine and cyano;

R³ is hydroxy or a group of the formula -X-C(=O)-Z,

wherein X represents NR^{'''} or O; wherein R^{'''} is hydrogen or C₁₋₄-alkyl, and

20 wherein Z is NR^{''}R^{'''}; wherein R^{''}, R^{'''} are independently of each other hydrogen or C₁₋₄-alkyl;

A signifies heterocyclyl-methyl, substituted heterocyclyl-methyl or heterocyclyl-methoxy-methyl,

25 wherein substituted heterocyclyl-methyl means heterocyclyl substituted with 1-2 substituents selected from C₁₋₄-alkyl and bromine.

5. Compounds as claimed in any one of claims 1 to 4 wherein

R¹ is C₁₋₄-alkyl;

R² is substituted phenyl,

30 wherein substituted phenyl means phenyl substituted with 1-3 substituents selected from fluorine, chlorine, bromine and cyano;

R^3 is a group of the formula $-X-C(=O)-Z$,

wherein X represents NR'''' or O; wherein R'''' is hydrogen or C_{1-4} -alkyl, and

wherein Z is $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl;

A signifies heterocyclyl-methyl.

6. Compounds as claimed in any one of claims 1 to 5 wherein

R^1 is iso-propyl;

R^2 is substituted phenyl,

wherein substituted phenyl means phenyl substituted with 1-3 substituents selected from chlorine and cyano;

R^3 is a group of the formula $-X-C(=O)-Z$,

wherein X represents O, and

wherein Z is $NR''R'''$; wherein R'' , R''' are independently of each other hydrogen or C_{1-4} -alkyl;

A signifies pyridyl-methyl.

7. A compound as claimed in claim 1 which compound is

5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol,

Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester,

Methylcarbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester,

5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methylamine,

1-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]urea,

N-[[5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]methanesulfonamide,

Methyl [[5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl]carbamate,

- 5 5-(3,5-Dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazole-3-methanol,

Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methoxymethyl]-1H-pyrazol-3-yl]methyl ester,

- 10 Carbamic acid [5-(3,5-dicyanophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester,

5-(3,5-Dichlorophenylthio)-1-ethyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol,

5-(3,5-Dichlorophenylthio)-1-isopropyl-4-(2-thenyl)-1H-pyrazole-3-methanol,

5-(3,5-Difluorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol,

- 15 Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-(2-thenyl)-1H-pyrazol-3-yl]methyl ester,

Carbamic acid [5-(3,5-difluorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester,

5-(3-Bromo-5-chlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol,

- 20 4-[(5-Bromo-2-methyl-4-pyrimidinyl)methyl]-5-(3,5-dichlorophenylthio)-1-isopropyl-1H-pyrazole-3-methanol,

5-(3,5-Dichlorophenylthio)-1-isopropyl-4-(3-methoxybenzyl)-1H-pyrazole-3-methanol,

5-(3,5-Dichlorophenylthio)-4-(3,4-difluorobenzyl)-1-isopropyl-1H-pyrazole-3-methanol,

5-(3,5-Dichlorophenylthio)-4-ethyl-1-isopropyl-1H-pyrazole-3-methanol,

- 25 Carbamic acid [5-(3,5-dichlorophenylthio)-4-ethyl-1-isopropyl-1H-pyrazol-3-yl]methyl ester,

Carbamic acid [5-(3,5-dichlorophenylthio)-4-(hydroxymethyl)-1-isopropyl-1H-pyrazol-3-yl]methyl ester,

3-[[5-(3,5-Dichlorophenylthio)-3-(hydroxymethyl)-1-isopropyl-1H-pyrazol-4-yl]methoxymethyl]benzonitrile,

5-(3,5-Dichlorophenylthio)-4-[(2-furfuryloxy)methyl]-1-isopropyl-1H-pyrazole-3-methanol,

5 5-(3,5-Dichlorophenylthio)-1-isopropyl-1H-pyrazole-3,4-dimethanol,

Carbamic acid [5-(3,5-dichlorophenylthio)-1-isopropyl-4-(3-methoxybenzyl)-1H-pyrazol-3-yl]methyl ester,

3-Chloro-5-[5-(hydroxymethyl)-2-isopropyl-4-[(4-pyridyl)methyl]-2H-pyrazol-3-ylthio]benzonitrile,

10 Carbamic acid [5-(3-chloro-5-cyanophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazol-3-yl]methyl ester or

5-(3-Chlorophenylthio)-1-isopropyl-4-[(4-pyridyl)methyl]-1H-pyrazole-3-methanol.

8. A compound of formula I, ether or pharmaceutically acceptable salt thereof, or
15 composition containing a compound of formula I, as claimed in any one of claims 1 to 7 for use as medicament.

9. Use of a compound of formula I, ether or pharmaceutically acceptable salt thereof, or
20 composition containing a compound of formula I, as claimed in any one of claims 1 to 7 for the preparation of a medicament for the treatment of a disease mediated by the human immunodeficiency virus (HIV).

10. A pharmaceutical composition comprising a pharmaceutically effective amount of a
25 compound, ether or pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7 and, if desired, a pharmaceutical inert carrier.

11. A process for preparing a medicament, which process comprises bringing a compound, ether or pharmaceutically acceptable salt thereof, as claimed in any one

- 58 -

of claims 1 to 7 into a galenical administration form together with a pharmaceutical inert carrier.

12. Use of a compound, ether or pharmaceutically acceptable salt thereof, as claimed in
5 any one of claims 1 to 7, in the treatment of a disease mediated by the human immunodeficiency virus (HIV).
13. A method of treating a disease mediated by the human immunodeficiency virus
10 (HIV) in a subject, which method comprises administering to said subject a pharmaceutically effective amount of a compound, ether or pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7.
14. The invention as herein before described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05898

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/06 C07D409/06 C07D403/06 C07D405/12 C07D231/18
 A61K31/415 A61K31/506 A61K31/4427 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 30907 A (HOFFMANN LA ROCHE) 18 April 2002 (2002-04-18) Page 77, lines 1-15: 4-(5-(3,5-dichloro-phenylsulfanyl)-1-isopropyl-3-hydroxy-methyl-1H-pyrazol-4-ylmethyl)-3-fluoro-pyridine. ---	1-5
P, A	WO 02 04424 A (CORBAU ROMUALD GASTON; PFIZER LTD (GB); WOOD ANTHONY (GB); MOWBRAY) 17 January 2002 (2002-01-17) Abstract; claims 1-75. ---	1-13
A	EP 0 786 455 A (SHIONOGI & CO) 30 July 1997 (1997-07-30) Claims 1-10; page 4, line 51 to page 30, line 54; page 31, lines 3-5. ---	1-13
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

29 October 2002

Date of mailing of the international search report

07/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Weisbrod, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05898

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GENIN M J ET AL: "NOVEL 1,5-DIPHENYLPYRAZOLE NONNUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS WITH ENHANCED ACTIVITY VERSUS THE DELAVIDINE-RESISTANT P236L MUTANT: LEAD IDENTIFICATION AND SAR OF 3- AND 4-SUBSTITUTED DERIVATIVES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 1034-1040, XP002178918 ISSN: 0022-2623 Page 1036, table 2. -----</p>	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/05898

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☒ Claims Nos.: 14
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 14

The scope of claim 14 is unclear to such an extent (Article 6 PCT) that the claim has not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/05898

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0230907	A	18-04-2002	AU 2165102 A	22-04-2002
			WO 0230907 A1	18-04-2002
WO 0204424	A	17-01-2002	AU 6776601 A	21-01-2002
			WO 0204424 A1	17-01-2002
			US 2002032184 A1	14-03-2002
EP 0786455	A	30-07-1997	AU 706095 B2	10-06-1999
			AU 4788896 A	19-04-1996
			BR 9509024 A	30-09-1997
			EP 0786455 A1	30-07-1997
			FI 971234 A	23-05-1997
			JP 3155009 B2	09-04-2001
			NO 971306 A	21-05-1997
			PL 320009 A1	01-09-1997
			US 5910506 A	08-06-1999
			CA 2200316 A1	04-04-1996
			CN 1158609 A	03-09-1997
			HU 77357 A2	30-03-1998
			WO 9610019 A1	04-04-1996
			RU 2157368 C2	10-10-2000
			TW 401404 B	11-08-2000
			US 6147097 A	14-11-2000